Table 2 Clinical presentation and treatment of 80 NSCLC patients with LM
Variable | N (%) |
|---|---|
Timing of metastasis | |
 Synchronous | 19 (23.8) |
 Metachronous | 61 (76.3) |
Time from diagnosis of lung cancer to LM, months | |
 Median (range) | 12.5 (−0.2 to 73.0) |
KPS score | |
 ≥ 80 | 21 (26.3%) |
 70–50 | 41 (51.3%) |
 ≤ 40 | 18 (22.5%) |
GCS score | |
 Less than 15 | 16 (20.0) |
With CNS symptoms | 80 (100.0) |
Modality of LM diagnosis | |
 MRI | 25 (31.3) |
 CSF cytology | 4 (5.0) |
 MRI + CSF cytology | 51 (63.8) |
Concurrent brain metastasis | 42 (52.5) |
Extra-CNS metastasis | 51 (63.8) |
Local treatment for LM | |
 WBRT | 38 (47.5) |
 VP shunt | 6 (7.5) |
 Ventricular external drainage | 7 (8.8) |
 Lumbar cistern drainage | 3 (3.8) |
Systematic treatment for LM | |
 Osimertinib | 25 (31.3) |
 Gefitinib | 12 (15.0) |
 Erlotinib | 4 (5.0) |
 Icotinib | 5 (6.3) |
 Afatinib | 1 (1.3) |
 Gefitinib followed by Osimertinib | 2 (2.5) |
 Bevacizumab | 9 (11.3) |
 Chemotherapy | 36 (45.0) |